Search Results
May 07, 2026, 08:30 ET ePlus Unveils Dynamic New ePlus.com Website Focusing on Customer Journeys
StageHERNDON, Va., May 7, 2026 /PRNewswire/ -- ePlus inc. (NASDAQ NGS: PLUS –
More news about: EPLUS INC.
May 06, 2026, 09:00 ET CHOW Investor Alert: ChowChow Cloud International Holdings Limited Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Underwriter Allegedly Ignored Manipulation Warnings: Levi & Korsinsky
ties-fraud-lawsuit---investors-with-losses-may-seek-to-lead-the-class-action-after-underwriter-allegedly-ignored-manipulation-warnings-levi--korsinsky-302763661.htmlSOURCE Levi & Korsinsky, LLP
More news about: Levi & Korsinsky, LLP
May 06, 2026, 08:30 ET ePlus VP of Customer Experience Deanna Davenport Spotlighted on the 2026 Women of the Channel Power 80 Solution Provider List
HERNDON, Va., May 6, 2026 /PRNewswire/ -- ePlus inc. (NASDAQ NGS: PLUS –
More news about: EPLUS INC.
Apr 29, 2026, 10:12 ET Europe Laboratory Information System (LIS) Market to Surpass USD 689.05 Million by 2031 - Exclusive Insights by Arizton
highlighting the growing global demand for scalable laboratory infrastructure. The rising adoption of digital pathology and next-generation sequencing (NGS) is further accelerating demand for platforms capable of managing large volumes of diagnostic data while supporting faster and more streamlined workflows.
More news about: Arizton Advisory & Intelligence
Apr 29, 2026, 08:30 ET Caris Life Sciences Publishes Study Validating Caris AI Insights for Temozolomide Benefit in Glioblastoma Patients
molecular and clinical data, is an AI-derived model designed to infer O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status from NGS data. MGMT promoter methylation is an established biomarker associated with response to TMZ therapy in GBM patients that is commonly assessed using pyrosequencing.
More news about: Caris Life Sciences
Apr 27, 2026, 13:24 ET Zymo Research Launches Fecal Microbiome Discovery Grant to Enable the Next Breakthroughs in Human Health
challenges.Zymo Research offers a comprehensive range of technologies, including sample collection reagents and devices, DNA/RNA purification kits, and NGS library preparation kits, as well as microbiomics, transcriptomics, epigenomics, and genomics sequencing services.In addition to its cutting-edge
More news about: Zymo Research Corp.
Apr 23, 2026, 11:01 ET Genomics Services Market Set to Reach $24.0 Billion by 2033, Growing at 11.2% CAGR
progressing steadily toward the $24.0 billion milestone by 2033. This growth trajectory is supported by the declining cost of next-generation sequencing (NGS) platforms, which have made large-scale genomic analysis economically viable across academic, clinical, and commercial settings. Advances in AI-driven
More news about: Allied Market Research
Apr 23, 2026, 09:00 ET Biotia Publishes Clinical Validation of Advanced UTI Test in Leading Microbiology Journal
the American Society for Microbiology Journal, Microbiology Spectrum. The study introduces and validates a novel next-generation sequencing (NGS) and machine learning–based approach for detecting urogenital pathogens and profiling antimicrobial resistance directly from clinical urine specimens
More news about: Biotia, Inc.
Apr 22, 2026, 23:37 ET AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches
MechanismsAcquired resistance remains a major challenge limiting the long-term benefit of targeted therapies. Using ctDNA-based next-generation sequencing (NGS), Abbisko conducted longitudinal genomic analyses comparing baseline and progression samples to elucidate resistance mechanisms to ABSK061:On-target
More news about: Abbisko Therapeutics
Apr 21, 2026, 11:00 ET Data Report: Gaia Dynamics Finds 30% Discrepancy Rate as U.S. Customs & Border Protection Increases Scrutiny
https://www.gaiadynamics.ai/whitepapers.About Gaia DynamicsGaia Dynamics is an AI-driven trade technology platform founded in 2025 in partnership with Andrew Ng's AI Fund. Headquartered in Palo Alto, California, the company leverages cutting-edge artificial intelligence to simplify complex processes in tariff
More news about: Gaia Dynamics
Apr 21, 2026, 08:49 ET This Earth Day, National Geographic Society-Backed Landmark Study Unveils a Bold New Model to Break Siloed Education--and Protect Wildlife
Day moment as the world grapples with accelerating environmental collapse and biodiversity loss. The research, funded by National Geographic Society (NGS) with publication support by Voices for Asian Elephants (https://www.vfaes.org/projects),
More news about: Voices for Asian Elephants
Apr 21, 2026, 08:00 ET FDA Breakthrough for First Viral-Integration MRD Liquid Biopsy in HCC -- New ctDNA Biomarker Class
CatCHimera leverages the fact that HBV integration sites are unique to each patient's tumor clones, enabling a tumor-informed MRD signal using capture-NGS and ddPCR without mutation calling.Published and presented clinical data (Hepatology; Cellular and Molecular Gastroenterology and Hepatology;
More news about: TCM Biotech
Apr 20, 2026, 22:23 ET Singapore imagines new ways of living at Milan Design Week with the opening of Prototype Island
lens to merge traditional Chinese calligraphy with the English alphabet into a system for constructing both digital and physical garments; Roger Ng's Lustre Series, reimagining the traditional Peranakan tea table with mother-of-pearl motifs using contemporary materials and digital production;
More news about: DesignSingapore Council
Apr 19, 2026, 21:00 ET ACT Genomics Tingkatkan Layanan Pengujian Genomik yang telah Diakui Secara Klinis Menjadi Panel 101 Gen dengan Waktu Pemrosesan Tujuh Hari
/PRNewswire/ -- ACT Genomics hari ini mengumumkan peningkatan signifikan seri ACTDrug®, layanan profil genomik berbasiskan next-generation sequencing (NGS). Panel terbaru kini mencakup 101 gen yang relevan secara klinis dan menawarkan waktu pemrosesan selama tujuh hari kerja. ACTDrug® menyediakan informasi
More news about: ACT Genomics
Apr 19, 2026, 21:00 ET ACT Genomics nâng cấp xét nghiệm hệ gen được công nhận lâm sàng lên bảng 101 gene với thời gian trả kết quả 7 ngày
Genomics hôm nay công bố nâng cấp quan trọng đối với dòng sản phẩm ACTDrug®, dịch vụ lập hồ sơ hệ gen dựa trên công nghệ giải trình tự gen thế hệ mới (NGS). Bảng gen cập nhật này hiện bao quát 101 gen có ý nghĩa lâm sàng, với thời gian trả kết quả trong vòng 7 ngày làm việc, được thiết kế nhằm cung
More news about: ACT Genomics
Apr 16, 2026, 08:59 ET Quintara Biosciences Introduces AmpValue: $4.99 Full-Length Nanopore Amplicon Sequencing
without compromising data integrity.The launch also strengthens Quintara Biosciences' broader amplicon sequencing portfolio across Sanger, NGS, and Nanopore-based platforms, giving researchers more options to match project needs with the right balance of speed, data quality, and cost. AmpValue
More news about: Quintara Biosciences
Apr 16, 2026, 08:00 ET Mount Sinai Health System and SOPHiA GENETICS Announce Collaboration to Advance Precision Cancer Care from AACR 2026
more than 4,000 oncology patients annually. Mount Sinai's Molecular Pathology team will leverage SOPHiA DDM™ to strengthen next-generation sequencing (NGS) capabilities for blood cancers and solid tumors. The Platform is designed to enable detection and interpretation of a wide range of complex genomic
More news about: SOPHiA GENETICS
Apr 16, 2026, 08:00 ET Mount Sinai Health System and SOPHiA GENETICS Announce Collaboration to Advance Precision Cancer Care from AACR 2026
more than 4,000 oncology patients annually. Mount Sinai's Molecular Pathology team will leverage SOPHiA DDM™ to strengthen next-generation sequencing (NGS) capabilities for blood cancers and solid tumors. The Platform is designed to enable detection and interpretation of a wide range of complex genomic
More news about: SOPHiA GENETICS
Apr 15, 2026, 12:05 ET Alida Biosciences Launches EpiPlex® Tri-Mod™ Service for Simultaneous Profiling of Three Key mRNA Modifications
AlidaBio launches the first commercial NGS solution for simultaneous pseudouridine, m6A, and inosine detection in RNA.The new service expands the EpiPlex platform, which is designed to
More news about: Alida Biosciences
Apr 15, 2026, 09:20 ET ePlus Launches Memory Optimization and Reclamation Assessment to Help Organizations Mitigate Chip Shortages
HERNDON, Va., April 15, 2026 /PRNewswire/ -- ePlus inc. (NASDAQ NGS: PLUS –
More news about: EPLUS INC.
Apr 09, 2026, 20:00 ET Oricell Therapeutics Closes $110 Million Pre-IPO Financing to Accelerate Global Development of Solid Tumor CAR-T Therapies
Partners, and a leading global healthcare fund. The syndicate included an international sovereign wealth fund, E-Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, and Talon Capital. Proceeds will be strategically allocated to accelerate Oricell's global expansion and clinical development,
More news about: Oricell Therapeutics Holdings Limited
Apr 07, 2026, 09:00 ET Google Just Accelerated the Post-Quantum Timeline. Every CISO in the World Is Now a Buyer
CyberArk acquisition and the more recent $3.35 billion Chronosphere deal have extended its platformization strategy into identity and observability, and NGS ARR ended the most recent quarter at $6.30 billion, up 33% year over year. On March 30, PANW shares popped on continued investor recognition that the
More news about: USA News Group
Apr 07, 2026, 08:00 ET Zymo Research and STORI Advance Early Pregnancy Detection with Cell-Free DNA Technology
sample collection, DNA/RNA purification, library preparation, microbiomics, transcriptomics, epigenomics, genomics, and Next-Generation Sequencing (NGS) services.In addition to its cutting-edge technologies, Zymo Research is committed to sustainability. By engineering environmentally friendly
More news about: Zymo Research Corp.
Apr 02, 2026, 09:00 ET BillionToOne Appoints Dr. Allen Chen as Vice President of Medical Affairs and Clinical Development, Oncology
translational research development for BillionToOne's Northstar oncology portfolio. Northstar Select® is an ultra-sensitive, 84-gene, single-molecule NGS-based ctDNA panel designed to identify actionable genomic alterations in patients with advanced solid tumors, giving oncologists a comprehensive liquid
More news about: BillionToOne
Apr 02, 2026, 08:15 ET CellCarta and Pillar Biosciences Announce Multi-Year Global Strategic Partnership to Expand Rapid, Decentralized Tumor Profiling for Oncology Clinical Trials
for drug development, and Pillar Biosciences, a leader in NGS-based oncology molecular diagnostics, today announced a global multi-year strategic partnership to broaden access to fast, operationally streamlined next-generation sequencing (NGS) tumor profiling for biopharma sponsors and clinical research
More news about: CellCarta